In addition, we recently reported that individuals within the ADNI dataset with a maternal history of dementia had increased AD biomarkers, including increased global PiB uptake, lower cerebrospinal fluid (CSF) amyloid-β and a higher tau/amyloid-β ratio than individuals with a paternal, or no family history of AD [7]. This evidence concerns the gene MAPT and Alzheimer disease.